Kelly K. Houck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kelly K. Houck has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Jeremy Hooker
Roudebush VA Med Ctr, Pain & Palliat Care, Indianapolis, IN USA
3 shared publications- Miranda Stratton
UNC Youth Behav Hosp, Butner, NC USA
3 shared publications - Amanda P. Ifeachor
Clinical Pharmacy Practitioner – Ambulatory Care (Gastrointestinal/Hepatitis C Virus Clinics), Veteran Health Indiana, Indianapolis, Indiana
2 shared publications - Elayne D. Ansara
Clinical Pharmacy Practitioner – Mental Health, Veteran Health Indiana, Indianapolis, Indiana
2 shared publications - Mallory Alexander
Roudebush VA Med Ctr, Veteran Hlth Indiana, Indianapolis, IN USA
2 shared publications Morgan Huh
OrthoIndy Hosp, Indianapolis, IN USA
2 shared publications
Latest Publications
- 11 October 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (11) , 1143-1152
A Survey of Veterans Affairs Pharmacists: Naloxone Prescribing and Perceived Barriers
Introduction: All Veterans Health Administration (VHA) sites have implemented the Opioid Overdose Education and Naloxone Distribution (OEND) program, which aims to reduce opioid‐involved overdose deaths. Objectives: Gaining a better understanding of pharmacists' perspectives toward naloxone is essential to developing effective pharmacy‐based naloxone services. This study investigated the perspectives of Veterans Affairs pharmacists toward prescribing naloxone and perceived barriers across multiple sites in the Veterans Integrated Service Network (VISN) 10. Methods: This was a multicenter, voluntary, and anonymous survey sent to pharmacists. Survey items reflecting pharmacists' perspectives were evaluated on a 5‐point Likert scale, aggregated according to domain, and adjusted for reverse scoring of select questions. Descriptive statistics were scaled from 1.0 to 5.0, representing least‐to‐most favorable perspectives. Results: A total of 124 surveys were completed and included in the data analysis. Domain‐aggregated adjusted means (standard deviation [SD]) for attitudes/beliefs, comfort, knowledge, fear of consequences, and time and resources were 4.08 (0.91), 3.77 (0.97), 3.64 (1.04), 3.69 (0.86), and 3.07 (1.09), respectively. Pharmacists who reported having formal training on naloxone prescribing or administration reported more favorable perspectives in the domains of comfort ( p = 0.001), knowledge ( p = 0.002), and time and resources ( p = 0.008). Pharmacists who had postgraduate residency training reported more favorable perspectives in the domains of attitudes/beliefs ( p = 0.007) and knowledge ( p = 0.01). Conclusion: Pharmacists' perspectives toward time and resources are a perceived barrier to naloxone prescribing. More favorable perspectives toward naloxone were detected among pharmacists with training on naloxone and pharmacists with postgraduate residency training.
- 11 October 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (11) , 1143-1152
A Survey of Veterans Affairs Pharmacists: Naloxone Prescribing and Perceived Barriers
Introduction: All Veterans Health Administration (VHA) sites have implemented the Opioid Overdose Education and Naloxone Distribution (OEND) program, which aims to reduce opioid‐involved overdose deaths. Objectives: Gaining a better understanding of pharmacists' perspectives toward naloxone is essential to developing effective pharmacy‐based naloxone services. This study investigated the perspectives of Veterans Affairs pharmacists toward prescribing naloxone and perceived barriers across multiple sites in the Veterans Integrated Service Network (VISN) 10. Methods: This was a multicenter, voluntary, and anonymous survey sent to pharmacists. Survey items reflecting pharmacists' perspectives were evaluated on a 5‐point Likert scale, aggregated according to domain, and adjusted for reverse scoring of select questions. Descriptive statistics were scaled from 1.0 to 5.0, representing least‐to‐most favorable perspectives. Results: A total of 124 surveys were completed and included in the data analysis. Domain‐aggregated adjusted means (standard deviation [SD]) for attitudes/beliefs, comfort, knowledge, fear of consequences, and time and resources were 4.08 (0.91), 3.77 (0.97), 3.64 (1.04), 3.69 (0.86), and 3.07 (1.09), respectively. Pharmacists who reported having formal training on naloxone prescribing or administration reported more favorable perspectives in the domains of comfort ( p = 0.001), knowledge ( p = 0.002), and time and resources ( p = 0.008). Pharmacists who had postgraduate residency training reported more favorable perspectives in the domains of attitudes/beliefs ( p = 0.007) and knowledge ( p = 0.01). Conclusion: Pharmacists' perspectives toward time and resources are a perceived barrier to naloxone prescribing. More favorable perspectives toward naloxone were detected among pharmacists with training on naloxone and pharmacists with postgraduate residency training.
- 10 August 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102168
Reprint of: Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- 10 August 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102168
Reprint of: Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- 25 December 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (3) , 101999
Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- 25 December 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (3) , 101999
Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- 6 November 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (2) , 551-556
Assessment of an education tool to improve knowledge and reduce stigma of a syringe service program (SSP) at a VA Medical Center
- 6 November 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (2) , 551-556
Assessment of an education tool to improve knowledge and reduce stigma of a syringe service program (SSP) at a VA Medical Center
- Open Access
- 1 June 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (3) , 181-186
Assessment of hepatitis C monitoring adherence after viral eradication in veterans with substance use to improve care and surveil reinfection
Introduction: Hepatitis C virus (HCV) incidence rates are rising for patients with substance use and/or SUDs. Guidelines provide monitoring recommendations to ensure remission after successful treatment. The study's objective was to identify gaps in follow-up for patients with documented substance use and/or SUD through assessment of adherence to guideline-recommended HCV RNA lab 12 months post-treatment. Methods: Patients treated for HCV through the Veteran Health Indiana Hepatitis C Pharmacy Clinic were retrospectively evaluated. Subjects were categorized based on the provider assigned for follow-up care after 12-week sustained virologic response (SVR12) labs (primary care provider [PCP] or HCV provider). The primary outcome was HCV RNA obtained 11 to 13 months post-treatment. Secondary outcomes were HCV RNA detected post-treatment, substance use, engagement in substance use treatment, and engagement with social work. Results: Two hundred forty-one patients were included in the HCV provider cohort and 139 in the PCP cohort. Forty-one patients did not have a specified clinic for follow-up treatment, and 20 patients did not achieve SVR12. Sixty-one patients (28%) in the HCV provider cohort completed a 12-month HCV RNA within 11 to 13 months post-treatment vs 15 patients (11%) in the PCP cohort (P ≤ .01). One patient had HCV RNA detected post-treatment. Discussion: This study reveals inadequate HCV post-treatment follow-up for patients with substance use and/or SUD. SUD is a chronic disease that requires continued monitoring to prevent complications. Further studies are needed to identify reinfection rates and improvements of care in this population.
- 1 June 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (3) , 181-186
Open AccessAssessment of hepatitis C monitoring adherence after viral eradication in veterans with substance use to improve care and surveil reinfection
Introduction: Hepatitis C virus (HCV) incidence rates are rising for patients with substance use and/or SUDs. Guidelines provide monitoring recommendations to ensure remission after successful treatment. The study's objective was to identify gaps in follow-up for patients with documented substance use and/or SUD through assessment of adherence to guideline-recommended HCV RNA lab 12 months post-treatment. Methods: Patients treated for HCV through the Veteran Health Indiana Hepatitis C Pharmacy Clinic were retrospectively evaluated. Subjects were categorized based on the provider assigned for follow-up care after 12-week sustained virologic response (SVR12) labs (primary care provider [PCP] or HCV provider). The primary outcome was HCV RNA obtained 11 to 13 months post-treatment. Secondary outcomes were HCV RNA detected post-treatment, substance use, engagement in substance use treatment, and engagement with social work. Results: Two hundred forty-one patients were included in the HCV provider cohort and 139 in the PCP cohort. Forty-one patients did not have a specified clinic for follow-up treatment, and 20 patients did not achieve SVR12. Sixty-one patients (28%) in the HCV provider cohort completed a 12-month HCV RNA within 11 to 13 months post-treatment vs 15 patients (11%) in the PCP cohort (P ≤ .01). One patient had HCV RNA detected post-treatment. Discussion: This study reveals inadequate HCV post-treatment follow-up for patients with substance use and/or SUD. SUD is a chronic disease that requires continued monitoring to prevent complications. Further studies are needed to identify reinfection rates and improvements of care in this population.
- 1 November 2020
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 60 (6) , 1037-1043.e3
HCV eradication in veterans with underlying mental health disorders and substance use
- 1 November 2020
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 60 (6) , 1037-1043.e3
HCV eradication in veterans with underlying mental health disorders and substance use